Dyne Therapeutics, Inc. (DYN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DYN Stock Price Chart Interactive Chart >
DYN Price/Volume Stats
|Current price||$6.70||52-week high||$22.17|
|Prev. close||$6.51||52-week low||$4.30|
|Day high||$6.72||Avg. volume||204,072|
|50-day MA||$6.23||Dividend yield||N/A|
|200-day MA||$10.30||Market Cap||346.08M|
Dyne Therapeutics, Inc. (DYN) Company Bio
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.
Most Popular Stories View All
DYN Latest News Stream
|Loading, please wait...|
DYN Latest Social Stream
View Full DYN Social Stream
Latest DYN News From Around the Web
Below are the latest news stories about Dyne Therapeutics Inc that investors may wish to consider to help them evaluate DYN as an investment opportunity.
Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51. Dyne rece
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live webcast will be available in the Investors & Media se
DYN Price Returns